These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27513651)

  • 1. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes.
    Deedwania PC; Pedersen TR; DeMicco DA; Breazna A; Betteridge DJ; Hitman GA; Durrington P; Neil A;
    Int J Cardiol; 2016 Nov; 222():548-556. PubMed ID: 27513651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study.
    Kostis JB; Breazna A; Deedwania PC; LaRosa JC;
    J Clin Hypertens (Greenwich); 2008 May; 10(5):367-76. PubMed ID: 18453796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
    Waters DD; LaRosa JC; Barter P; Fruchart JC; Gotto AM; Carter R; Breazna A; Kastelein JJ; Grundy SM
    J Am Coll Cardiol; 2006 Nov; 48(9):1793-9. PubMed ID: 17084252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
    Bangalore S; Fayyad R; Messerli FH; Laskey R; DeMicco DA; Kastelein JJ; Waters DD
    Am J Cardiol; 2017 Feb; 119(3):379-387. PubMed ID: 27939230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).
    Frey P; Waters DD; DeMicco DA; Breazna A; Samuels L; Pipe A; Wun CC; Benowitz NL
    Am J Cardiol; 2011 Jan; 107(2):145-50. PubMed ID: 21129718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
    Hsue PY; Bittner VA; Betteridge J; Fayyad R; Laskey R; Wenger NK; Waters DD
    Am J Cardiol; 2015 Feb; 115(4):447-53. PubMed ID: 25637322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
    Barter P; Gotto AM; LaRosa JC; Maroni J; Szarek M; Grundy SM; Kastelein JJ; Bittner V; Fruchart JC;
    N Engl J Med; 2007 Sep; 357(13):1301-10. PubMed ID: 17898099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis.
    Ports WC; Fayyad R; DeMicco DA; Laskey R; Wolk R
    Clin Drug Investig; 2017 Aug; 37(8):775-785. PubMed ID: 28573499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
    Arsenault BJ; Boekholdt SM; Hovingh GK; Hyde CL; DeMicco DA; Chatterjee A; Barter P; Deedwania P; Waters DD; LaRosa JC; Pedersen TR; Kastelein JJ;
    Circ Cardiovasc Genet; 2012 Feb; 5(1):51-7. PubMed ID: 22135385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
    Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
    J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
    Bangalore S; Breazna A; DeMicco DA; Wun CC; Messerli FH;
    J Am Coll Cardiol; 2015 Apr; 65(15):1539-48. PubMed ID: 25881936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
    Deedwania PC; Shepherd J; Breazna A; DeMicco DA;
    Diabetes Obes Metab; 2016 Jan; 18(1):56-63. PubMed ID: 26434404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
    Amarenco P; Goldstein LB; Messig M; O'Neill BJ; Callahan A; Sillesen H; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2009 Jul; 40(7):2486-92. PubMed ID: 19461031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
    Bangalore S; Fayyad R; Kastelein JJ; Laskey R; Amarenco P; DeMicco DA; Waters DD
    Am J Med; 2016 Apr; 129(4):384-91. PubMed ID: 26551986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region.
    Asia Pacific Cohort Studies Collaboration
    Circulation; 2005 Nov; 112(22):3384-90. PubMed ID: 16301345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.